13 pharmaceutical companies disclosed annual report forecasts, 5 expected to double their net profit

The annual report forecast has been drawn
.
According to Flush data, as of January 6, 2022, 100 A-share listed companies have released 2021 annual report performance forecasts
.
Among them, in the pharmaceutical industry, according to the author's review, a total of 13 listed pharmaceutical companies have disclosed their annual performance forecasts for 2021, including Hualan, Yanan Bikang, Nhua Pharmaceutical, Zuoli Pharmaceutical, Haili Bio, Kefu Medical, etc.
company
.
The pharmaceutical industry (Source: Pharmaceutical Network) 13 pharmaceutical companies disclose annual report forecasts From the types of annual performance forecasts released by these 13 pharmaceutical companies, there are 3 companies with expected performance increases in 2021, namely Enhua Pharmaceutical, Keke Fu Medical and Zhenghai Biological; 6 companies whose performance has increased significantly, including Hualan, Zuoli Pharmaceutical, Haili Bio, Kaipu Bio, Dongbao Bio, and Mingde Bio; in addition, 3 companies have turned losses in performance, 1 loss in advance
.
Judging from the growth rate of net profit in the annual report, among the listed pharmaceutical companies whose annual reports are positive, 5 companies are expected to increase their net profit by more than 100% year-on-year, including Hualan, Yanan Bikang, Kaipu Bio, Mingde Bio, and Zhongsheng.
Pharmaceuticals; Zuoli Pharmaceutical, Dongbao Bio, etc.
have a median increase of 50%-100% in net profit
.
From the perspective of the upper limit of net profit, Yan'an Bikang and Mingde Biology are in the forefront, and the net profit in 2021 may exceed 1 billion yuan
.
In addition, the net profit of many pharmaceutical companies such as Hualan Co.
, Ltd.
, Enhua Pharmaceutical, Zuoli Pharmaceutical, Zhenghai Biological, and Zhongsheng Pharmaceutical is more than 100 million yuan
.
Among them, Mingde Bio expects to achieve a net profit cap of 1.
5 billion yuan from January 1, 2021 to December 31, 2021
.
According to the data, Mingde Bio is an enterprise mainly engaged in the independent research and development, production and sales of in vitro diagnostic reagents and diagnostic equipment.
The company focuses on three major product lines of immune products, molecular diagnostic products and blood gas products in the POCT field
.
It is reported that during the reporting period, the company’s sales of nucleic acid detection reagents increased significantly, as well as foreign trade orders for overseas detection reagents and related income increased significantly, driving performance growth.
The penetration rate in primary medical care and grade hospitals has gradually increased, and the related income has steadily increased
.
From the perspective of the company's market value, among the listed pharmaceutical companies forecasting their 2021 performance, those with a new market value of more than 10 billion yuan include Yan'an Bikang, Enhua Pharmaceutical, Haili Bio, Kefu Medical, and Kanghong Pharmaceutical
.
Among them, Kanghong Pharmaceutical currently ranks among the top in new market value, reaching 18.
978 billion yuan.
The company released the 2021 annual report performance forecast on October 28, 2021.
It is expected that the net profit attributable to shareholders of listed companies in 2021 will turn losses into profits year-on-year
.
Regarding the reasons for the changes in the annual performance of 2021, Kanghong Pharmaceutical stated that in 2021, the company will continue to optimize its operation and management to adapt to changes in the industry environment, and its operating performance will continue to be stable
.
In addition, from the perspective of sub-sectors, the pharmaceutical companies that currently disclose annual report forecasts are concentrated in sub-sectors such as chemical drugs, in vitro diagnostics, and medical devices
.
Five companies are expected to increase their net profit by more than 100% year-on-year.
Specifically, Hualan, Yanan Bikang, Kaipu Bio, Mingde Bio, and Zhongsheng Pharmaceutical are expected to increase their net profit by more than 100% year-on-year
.
Among them, Hualan expects that from January to December 2021, the net profit attributable to owners of the parent company will be about 196 million to 266 million yuan, an increase of 141.
64% to 226.
92%
.
The main business of Hualan Co.
, Ltd.
is: research and development, production and sales of direct contact injection pharmaceutical packaging materials
.
On December 29, 2021, the secretary of the board of Hualan shares replied on the interactive platform that the company's profit in the first three quarters of 2021 increased significantly compared with the same period last year, and the sales of vaccine rubber stoppers increased significantly
.
Yan'an Bikang expects a net profit of 950 million to 1 billion yuan in 2021, an increase of 188.
72% to 193.
39%, and a basic earnings per share of 0.
6199 yuan to 0.
6526 yuan
.
Yan'an Bikang is a pharmaceutical enterprise group integrating the production and marketing of APIs, proprietary Chinese medicines, chemicals, biological preparations, vaccines, health products, and health drinks.

.
Regarding the reasons for the increase in performance in 2021, the announcement shows that the company's subsidiary Jiangsu Jiujiujiu Technology is engaged in the lithium hexafluorophosphate business.
In 2021, the price of lithium hexafluorophosphate will increase by 635.
71% compared with the low price in 2020, making Jiujiujiu's profit compared with the same period of the previous year.
In addition, the company will receive more than 200 million government subsidies in 2021, which will improve its performance
.
Kaipu Bio expects to achieve a net profit of 800 million to 860 million yuan in 2021, an increase of 120.
59% to 137.
14%, and a basic earnings per share of 2.
73 yuan to 2.
93 yuan
.
Kaipu Bio is a domestic provider of molecular diagnostic products and services.
Related products are widely used in hospital clinical diagnosis and large-scale population screening
.
During the reporting period, the company continued to promote the integrated business model of "nucleic acid testing products + medical testing services", continued to implement the "nucleic acid 99 strategy" and "Kaipu B53 nucleic acid remote strategic service plan", and the company's third-party medical laboratories actively participated Due to the epidemic prevention and control work, the business has achieved rapid development
.
Mingde Bio expects a net profit of 1.
3 billion yuan to 1.
5 billion yuan last year, an increase of 177.
23% to 219.
88%, and a basic earnings per share of 13.
71 yuan to 15.
83 yuan
.
Mingde Bio is a company specializing in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments (POCT\molecular diagnosis\chemiluminescence\blood gas, etc.
) and mobile ECG products
.
In 2021, the growth of the company's performance is closely related to the substantial growth in the sales of nucleic acid detection reagents
.
Zhongsheng Pharmaceutical expects to achieve a net profit of 330 million to 390 million yuan in 2021, a year-on-year change of 177.
35% to 191.
42%
.
Basic earnings per share range from 0.
41 yuan to 0.
49 yuan
.
Zhongsheng Pharmaceutical is an enterprise integrating drug research and development, production and sales
.
The company stated that the net profit in 2021 will turn losses into profits, mainly due to the loss of the previous year's performance due to the impact of the impairment of goodwill
.